Validation of histone deacetylase 3 as a therapeutic target in castration ‐resistant prostate cancer

ConclusionsOur studies provide strong rationale for the near‐term development of specific HDAC3 inhibitors for the treatment of CRPC.

Source: The Prostate - December 15, 2017 Category: Urology & Nephrology Authors: Abigail B. McLeod, James P. Stice, Suzanne E. Wardell, Holly M. Alley, Ching ‐yi Chang, Donald P. McDonnell Tags: ORIGINAL ARTICLE Source Type: research